Top

Published in:

Open Access 01-04-2013 | Research

Quality of life and pruritus in patients with severe sepsis resuscitated with hydroxyethyl starch long-term follow-up of a randomised trial

Authors: Piotr Wittbrodt, Nicolai Haase, Dominika Butowska, Robert Winding, Jesper B Poulsen, Anders Perner, the 6S trial group and the Scandinavian Critical Care Trials Group

Published in: Critical Care | Issue 2/2013

Abstract

Introduction

The effects of hydroxyethyl starch (HES) on patient-centered outcome measures have not been fully described in patients with severe sepsis. We assessed health-related quality of life (HRQoL) and the occurrence of pruritus in patients with severe sepsis randomized to resuscitation with HES 130/0.42 or Ringer's acetate.

Methods

We did post hoc analyses of the Danish survivors (n = 295) of the 6S trial using mailed questionnaires on self-perceived HRQoL (Short Form (SF) - 36) and pruritus.

Results

Median 14 months (interquartile range 10 to 18) after randomization, 182 (61%) and 185 (62%) completed questionnaires were obtained for the assessment of HRQoL and pruritus, respectively. Responders were older than nonresponders, but characteristics at randomization of the responders in the HES vs. Ringer's groups were comparable. At follow-up, the patients in the HES group had lower mental component summary scores than those in the Ringer's group (median 45 (interquartile range 36 to 55) vs. 53 (39 to 60), P = 0.01). The group differences were mainly in the scales of vitality and mental health. There was no difference in the physical component summary scores between groups, but patients in the HES group scored worse in bodily pain. Forty-nine percent of patients allocated to HES had experienced pruritus at any time after ICU discharge compared to 43% of those allocated to Ringer's (relative risk 1.13, 95% confidence interval 0.83 to 1.55, P = 0.43).

Conclusions

At long-term follow-up patients with severe sepsis assigned to resuscitation with HES 130/0.42 had worse self-perceived HRQoL than those assigned to Ringer's acetate whereas there were no statistically significant differences in the occurrence of pruritus.

Available only for authorised users

Finfer S, Liu B, Taylor C, Bellomo R, Billot L, Cook D, Du B, McArthur C, Myburgh J: Resuscitation fluid use in critically ill adults: an international cross-sectional study in 391 intensive care units. Crit Care 2010, 14: R185. 10.1186/cc9293PubMedCentralCrossRefPubMed

Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, Glass P, Lipman J, Liu B, McArthur C, McGuinness S, Rajbhandari D, Taylor CB, Webb SA, CHEST Investigators; Australian and New Zealand Intensive Care Society Clinical Trials Group: Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 2012, 367: 1901-1911. 10.1056/NEJMoa1209759CrossRefPubMed

Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Aneman A, Madsen KR, Moller MH, Elkjaer JM, Poulsen LM, Bendtsen A, Winding R, Steensen M, Berezowicz P, Søe-Jensen P, Bestle M, Strand K, Wiis J, White JO, Thornberg KJ, Quist L, Nielsen J, Andersen LH, Holst LB, Thormar K, Kjældgaard AL, Fabritius ML, Mondrup F, Pott FC, Møller TP, Winkel P, Wetterslev J, 6S Trial Group; Scandinavian Critical Care Trials Group: Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med 2012, 367: 124-134. 10.1056/NEJMoa1204242CrossRefPubMed

Barron ME, Wilkes MM, Navickis RJ: A systematic review of the comparative safety of colloids. Arch Surg 2004, 139: 552-563. 10.1001/archsurg.139.5.552CrossRefPubMed

Guidet B, Martinet O, Boulain T, Philippart F, Poussel JF, Maizel J, Forceville X, Feissel M, Hasselmann M, Heininger A, Van Aken H: Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: The CRYSTMAS study. Crit Care 2012, 16: R94. 10.1186/cc11358PubMedCentralCrossRefPubMed

Ickx BE, Bepperling F, Melot C, Schulman C, Van der Linden PJ: Plasma substitution effects of a new hydroxyethyl starch HES 130/0.4 compared with HES 200/0.5 during and after extended acute normovolaemic haemodilution. Br J Anaesth 2003, 91: 196-202. 10.1093/bja/aeg159CrossRefPubMed

Kimme P, Jannsen B, Ledin T, Gupta A, Vegfors M: High incidence of pruritus after large doses of hydroxyethyl starch (HES) infusions. Acta Anaesthesiol Scand 2001, 45: 686-689. 10.1034/j.1399-6576.2001.045006686.xCrossRefPubMed

Morgan PW, Berridge JC: Giving long-persistent starch as volume replacement can cause pruritus after cardiac surgery. Br J Anaesth 2000, 85: 696-699. 10.1093/bja/85.5.696CrossRefPubMed

Rudolf J: Hydroxyethyl starch for hypervolemic hemodilution in patients with acute ischemic stroke: a randomized, placebo-controlled phase II safety study. Cerebrovasc Dis 2002, 14: 33-41. 10.1159/000063721CrossRefPubMed

10.

Waitzinger J, Bepperling F, Pabst G, Opitz J: Hydroxyethyl starch (HES) [130/0.4], a new HES specification: pharmacokinetics and safety after multiple infusions of 10% solution in healthy volunteers. Drugs R D 2003, 4: 149-157.CrossRefPubMed

11.

Wiedermann CJ: Complications of hydroxyethyl starch in acute ischemic stroke and other brain injuries. Pathophysiol Haemost Thromb 2003, 33: 225-228. 10.1159/000081513CrossRefPubMed

12.

Woessner R, Grauer MT, Dieterich HJ, Bepperling F, Baus D, Kahles T, Georgi S, Bianchi O, Morgenthaler M, Treib J: Influence of a long-term, high-dose volume therapy with 6% hydroxyethyl starch 130/0.4 or crystalloid solution on hemodynamics, rheology and hemostasis in patients with acute ischemic stroke. Results of a randomized, placebo-controlled, double-blind study. Pathophysiol Haemost Thromb 2003, 33: 121-126. 10.1159/000077819CrossRefPubMed

13.

Ridley S, Morris S: Cost effectiveness of adult intensive care in the UK. Anaesthesia 2007, 62: 547-554. 10.1111/j.1365-2044.2007.04997.xCrossRefPubMed

14.

Perner A, Haase N, Wetterslev J, Aneman A, Tenhunen J, Guttormsen AB, Klemenzson G, Pott F, Bodker KD, Badstolokken PM, Bendtsen A, Søe-Jensen P, Tousi H, Bestle M, Pawlowicz M, Winding R, Bülow HH, Kancir C, Steensen M, Nielsen J, Fogh B, Madsen KR, Larsen NH, Carlsson M, Wiis J, Petersen JA, Iversen S, Schøidt O, Leivdal S, Berezowicz P, Pettilä V, Ruokonen E, Klepstad P, Karlsson S, Kaukonen M, Rutanen J, Karason S, Kjældgaard AL, Holst LB, Wernerman J, Scandinavian Critical Care Trials Group: Comparing the effect of hydroxyethyl starch 130/0.4 with balanced crystalloid solution on mortality and kidney failure in patients with severe sepsis (6S--Scandinavian Starch for Severe Sepsis/Septic Shock trial): study protocol, design and rationale for a double-blinded, randomised clinical trial. Trials 2011, 12: 24. 10.1186/1745-6215-12-24PubMedCentralCrossRefPubMed

15.

Chrispin PS, Scotton H, Rogers J, Lloyd D, Ridley SA: Short Form 36 in the intensive care unit: assessment of acceptability, reliability and validity of the questionnaire. Anaesthesia 1997, 52: 15-23. 10.1111/j.1365-2044.1997.015-az014.xCrossRefPubMed

16.

Poulsen JB, Moller K, Kehlet H, Perner A: Long-term physical outcome in patients with septic shock. Acta Anaesthesiol Scand 2009, 53: 724-730. 10.1111/j.1399-6576.2009.01921.xCrossRefPubMed

17.

Wehler M, Geise A, Hadzionerovic D, Aljukic E, Reulbach U, Hahn EG, Strauss R: Health-related quality of life of patients with multiple organ dysfunction: individual changes and comparison with normative population. Crit Care Med 2003, 31: 1094-1101. 10.1097/01.CCM.0000059642.97686.8BCrossRefPubMed

18.

Ware JE Jr, Gandek B, Kosinski M, Aaronson NK, Apolone G, Brazier J, Bullinger M, Kaasa S, Leplege A, Prieto L, Sullivan M, Thunedborg K: The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 1998, 51: 1167-1170. 10.1016/S0895-4356(98)00108-5CrossRefPubMed

19.

Bjorner JB, Kreiner S, Ware JE, Damsgaard MT, Bech P: Differential item functioning in the Danish translation of the SF-36. J Clin Epidemiol 1998, 51: 1189-1202. 10.1016/S0895-4356(98)00111-5CrossRefPubMed

20.

Bjorner JB, Damsgaard MT, Watt T, Groenvold M: Tests of data quality, scaling assumptions, and reliability of the Danish SF-36. J Clin Epidemiol 1998, 51: 1001-1011. 10.1016/S0895-4356(98)00092-4CrossRefPubMed

21.

Ware JE, Snow KK, Kosinski M, Gandek B: SF-36 Health Survey: Manual and Interpretation Guide. Boston: The Health Institute, New England Medical Center; 1993.

22.

Pillebout E, Nochy D, Hill G, Conti F, Antoine C, Calmus Y, Glotz D: Renal histopathological lesions after orthotopic liver transplantation (OLT). Am J Transplant 2005, 5: 1120-1129. 10.1111/j.1600-6143.2005.00852.xCrossRefPubMed

23.

Christidis C, Mal F, Ramos J, Senejoux A, Callard P, Navarro R, Trinchet JC, Larrey D, Beaugrand M, Guettier C: Worsening of hepatic dysfunction as a consequence of repeated hydroxyethylstarch infusions. J Hepatol 2001, 35: 726-732. 10.1016/S0168-8278(01)00200-8CrossRefPubMed

24.

Schmidt-Hieber M, Loddenkemper C, Schwartz S, Arntz G, Thiel E, Notter M: Hydrops lysosomalis generalisatus--an underestimated side effect of hydroxyethyl starch therapy? Eur J Haematol 2006, 77: 83-85. 10.1111/j.1600-0609.2006.00657.xCrossRefPubMed

25.

Department Of Health & Human Services: NDA review memo (mid-cycle).[http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/NewDrugApplicationsNDAs/UCM083393.pdf]

26.

Reich A, Stander S, Szepietowski JC: Drug-induced pruritus: a review. Acta Derm Venereol 2009, 89: 236-244. 10.2340/00015555-0650CrossRefPubMed

27.

Stander S, Bone HG, Machens HG, Aberle T, Burchard W, Prien T, Luger TA, Metze D: Hydroxyethyl starch does not cross the blood-brain or the placental barrier but the perineurium of peripheral nerves in infused animals. Cell Tissue Res 2002, 310: 279-287. 10.1007/s00441-002-0644-6CrossRefPubMed

28.

Heyland DK, Hopman W, Coo H, Tranmer J, McColl MA: Long-term health-related quality of life in survivors of sepsis. Short Form 36: a valid and reliable measure of health-related quality of life. Crit Care Med 2000, 28: 3599-3605. 10.1097/00003246-200011000-00006CrossRefPubMed

29.

Little RJ, D'Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT, Frangakis C, Hogan JW, Molenberghs G, Murphy SA, Neaton JD, Rotnitzky A, Scharfstein D, Shih WJ, Siegel JP, Stern H: The prevention and treatment of missing data in clinical trials. N Engl J Med 2012, 367: 1355-1360. 10.1056/NEJMsr1203730PubMedCentralCrossRefPubMed

30.

Hays RD, Woolley JM: The concept of clinically meaningful difference in health-related quality-of-life research. How meaningful is it? Pharmacoeconomics 2000, 18: 419-423. 10.2165/00019053-200018050-00001CrossRefPubMed

31.

Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D: Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics 1999, 15: 141-155. 10.2165/00019053-199915020-00003CrossRefPubMed

Title: Quality of life and pruritus in patients with severe sepsis resuscitated with hydroxyethyl starch long-term follow-up of a randomised trial
Authors: Piotr Wittbrodt
Nicolai Haase
Dominika Butowska
Robert Winding
Jesper B Poulsen
Anders Perner
the 6S trial group and the Scandinavian Critical Care Trials Group
Publication date: 01-04-2013
Publisher: BioMed Central
Published in: Critical Care / Issue 2/2013
Electronic ISSN: 1364-8535
DOI: https://doi.org/10.1186/cc12586

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Quality of life and pruritus in patients with severe sepsis resuscitated with hydroxyethyl starch long-term follow-up of a randomised trial

Abstract

Introduction

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2013

Comments on the use of expiratory time constant for determinations of plateau pressure, respiratory system compliance, and total resistance

Patient monitoring alarms in the ICU and in the operating room

Serum adipocyte fatty acid-binding protein in the critically ill

Initial ventilator settings for critically ill patients

Re-evaluating high-frequency oscillation for ARDS: Would a targeted approach be successful?

Visitation policies and practices in US ICUs